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SYSTEMATIC REVIEW
Congenital heart defects in offspring of women 
with Type 2 diabetes – a systematic review
Anna Slot1, 2, Nina Bonne Eriksen1, 2, Lene Ringholm1, 3, 4, Peter Damm1, 2, 5 & Elisabeth R. Mathiesen1, 2, 3
The number of pregnant women with Type 2 diabetes 
has increased substantially in recent decades and, in 
some countries, it now exceeds the number of pregnant 
women with Type 1 diabetes [1]. 
While it is well described that the risk of congenital 
malformations is increased by at least two-fold in off-
spring of women with Type 1 diabetes [2], data on off-
spring of women with Type 2 diabetes are scarcer. The 
most common congenital malformations are heart de-
fects, both in offspring of women with diabetes and in 
the background population [3]. Congenital heart de-
fects (CHD) often have significant clinical implications 
for the offspring and thus a major impact on the whole 
family. Whether the risk of CHD in offspring of women 
with Type 2 diabetes is comparable to the risk in off-
spring of women with Type 1 diabetes has only been 
sparsely investigated [1, 4], and reviews exploring this 
topic could not be identified in the literature. A strong 
positive correlation between glycaemic control and the 
prevalence of congenital malformations, specifically 
CHD, has been described among offspring of women 
with Type 1 diabetes [5]. The association between con-
genital malformations and hyperglycaemia is poorly 
understood, but hyperglycaemia may induce oxidative 
stress and cell-membrane damage, causing apoptosis 
and thereby disturbing organogenesis [5, 6]. Animal 
studies have indicated that the developing heart is par-
ticularly sensitive to hyperglycaemia [7, 8]. 
The aim of this review was to estimate the preva-
lence of CHD in offspring of women with Type 2 diabe-
tes compared with offspring of women with Type 1 dia-
betes and offspring of the background population.
METHODS 
This review was conducted in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) guidelines. However, several 
items were not applicable for this review, i.e. the study 
ABSTRACT
INTRODUCTION: The risk of congenital heart defects in the 
offspring of women with Type 2 diabetes is only sparsely 
described. The aim of this review was to estimate the 
prevalence of congenital heart defects in offspring of 
women with Type 2 diabetes in comparison to offspring of 
women with Type 1 diabetes and to offspring of the 
background population.
METHODS: This systematic review followed the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) guidelines. A literature search was performed in 
the PubMed, Embase and Cochrane databases. Studies 
were included if they were published from 2007 to 2018, 
comprised a minimum of 200 offspring of women with Type 
2 diabetes and examined the prevalence of congenital heart 
defects. 
RESULTS: Five cohort studies with a total of 23,845 
offspring of women with Type 2 diabetes were included. The 
studies were heterogeneous with respect to method of 
diagnosis and whether terminated pregnancies were 
included, and a meta-analysis could not be performed. The 
mean prevalence of congenital heart defects was 44 (range: 
26-65) per 1,000 offspring. The mean relative risk was 0.82 
(range: 0.53-1.01) compared with offspring of women with 
Type 1 diabetes, and 3.83 (range: 2.53-5.49) compared with 
the background population. A positive association was 
described between the prevalence of congenital heart 
defects and the maternal glycated haemoglobin level, but 
not with medical treatment. 
CONCLUSIONS: The risk of congenital heart defects among 
offspring of women with Type 2 diabetes was comparable to 
that of offspring of women with Type 1 diabetes and almost 
four times higher than in the background population
 ▶ The risk of congenital heart defects among offspring 
of women with Type 2 diabetes was comparable to 
that of offspring of women with Type 1 diabetes and 
almost four times higher than the risk in the back­
ground population.
 ▶ The mean prevalence of congenital heart defects in 
the offspring of women with Type 2 diabetes was 44 
per 1,000 offspring.
 ▶ These findings emphasise the importance of preg­
nancy planning in women with Type 2 diabetes.
 ▶ More research into the pathophysiology and predicting 
factors of congenital heart defects in offspring of 
women with Type 2 diabetes is warranted. 
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was not based on a review protocol and statistical ana-
lysis was not conducted.
The review was based on a search for all popula-
tion- or region-based cohort studies including offspring 
of women with Type 2 diabetes published from January 
2007 to February 2018. The PubMed, Embase and 
Cochrane databases were searched using basically the 
following Medical Subject Heading (MESH) terms 
(PubMed), Subject Heading terms (Embase) and text 
words: congenital abnormalities/congenital abnormal-
ity/congenital anomalies/congenital anomaly/congen-
ital malformations/congenital malformation/cardiac 
anomalies/cardiac anomaly/congenital heart defect/
congenital heart disease AND diabetes mellitus Type 2/
pregnancy in diabetics/diabetes Type 2/T2DM/Type 2 
diabetes/pre-gestational diabetes/pregestational dia-
betes/pre-pregnancy diabetes/non-insulin dependent 
diabetes/maternal diabetes AND pregnancies/preg-
nancy/pregnant/gestation. 
The search was conducted on 1 February 2018. In 
total, 521 titles were identified in PubMed, 1,032 titles 
in Embase and 429 titles in the Cochrane database. 
Based on the titles, 120, 144 and 12 abstracts, respect-
ively, were read by the first author. 
The inclusion criteria were studies each including 
data on CHD in a minimum of 200 offspring of women 
with Type 2 diabetes from independent cohorts. The 
cohort size was a pragmatic choice made to minimise 
the uncertainty when evaluating the prevalence of rare 
events such as CHD in a relatively small sample size.
A total of seven studies with cohorts counting more 
than 200 offspring were identified. Hereof, three were 
Canadian cohort studies [9-11]. The national Canadian 
cohort study [9] with the longest observation period 
and the largest cohort size included the observation  
periods used in the two other Canadian studies [10, 
11], indicating that these three cohorts were not inde-
pendent. Thus, only five studies [9, 12-15] were in-
cluded in this review.
The mean prevalence and mean relative risk of CHD 
for the included studies were calculated without 
weight ing in relation to the size of the included popu-
lations.  
RESULTS
The five studies in this review [9, 12-15] included an 
estimated total number of 23,845 offspring of women 
with Type 2 diabetes, ranging from 371 to 11,019  
(Table 1). 
The studies were mainly nation-wide cohort studies 
from Canada, Taiwan, Denmark and Norway [9, 13-
15] that used the International Classification of 
Diseases, ninth version (ICD-9) or ICD-10 diagnosis 
codes, to identify the cases, but in one retrospective co-
hort study from the US, ultrasound heart examinations 
of all offspring born by women with diabetes was per-
formed [12] (Table 1). Two studies [12, 13] included 
pregnancies that were terminated due to antenatally 
diagnosed foetal CHD, whereas the remaining three 
studies [9, 14, 15] did not report on this issue. Three 
studies [12-14] excluded CHD existing together with 
chromosomal anomalies, whereas the two remaining 
studies [9, 15] did not report on chromosomal anom-
alies. Three studies [12-14] included only singleton 
pregnancies, and two studies [9, 15] included all preg-
nancies, but data were given per offspring. Due to the 
heterogeneity of the studies, it was not possible to per-
form a formal meta-analysis and sub-analysis. Apart 
from excluding studies with less than 200 offspring, 
formal risk of bias within or between studies was not 
evaluated. 
When the relative risk of CHD was not presented in 
the individual studies, it was calculated as the risk of 
CHD in offspring of women with diabetes divided with 
the risk of CHD in offspring of the background popula-
tion [9, 14, 15]. When the prevalence was not given, it 
was estimated as the relative risk in offspring of women 
with Type 2 diabetes (2.53) times the prevalence in the 
backgrounds population (0.0102), corresponding to a 
prevalence of 25.8 per 1,000 offspring of women with 
Type 2 diabetes (Table 1) [13].
In three studies [9, 13, 15], the exact number of off-
spring of women with Type 2 diabetes was not given 
and therefore it was estimated in the following man-
ner: 
In the Canadian study [9], the prevalence of off-
spring of women with Type 2 diabetes increased from 
0.0019 to 0.0047, and we estimated the average preva-
lence of offspring of women with Type 2 diabetes to 
0.0033. With a total number of 2,839,680 offspring 
and a prevalence of offspring of women with diabetes 
of 0.0033, this equals 9,371 offspring of women with 
Type 2 diabetes.
In the Norwegian study [13], the prevalence of off-
spring of women with Type 2 diabetes increased from 
0.00106 to 0.00271, and we estimated the average 
prevalence of offspring of women with Type 2 diabetes 
to 0.00189. With a total number of 914,427 offspring 
and a prevalence of offspring of women with Type 2  
diabetes of 0.00189, this equals 1,728 offspring of 
women with Type 2 diabetes. 
In the Taiwanese study [15], the total number of 
offspring of women with Type 2 diabetes was estimated 
as the total number of offspring with CHD among 
women with Type 2 diabetes (n = 628) divided by the 
prevalence of CHD in offspring of women with Type 2 
diabetes of 0.9579, equalling 11,019 offspring. 
The same calculations were performed for women 
with Type 1 diabetes (Table 2).
The mean prevalence of CHD among the offspring 
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of women with Type 2 diabetes was 44 (range: 26-65) 
per 1,000 offspring, corresponding to a relative risk of 
3.83 (range: 2.53-5.49) compared with the back-
ground population and 0.82 (range: 0.53-1.01) com-
pared with the offspring of women with Type 1 dia-
betes (Table 2).
There was a positive relation between glycated hae-
moglobin (HbA1c) level and CHD prevalence in a mixed 
population from the US, where approximately two 
thirds of the women had Type 2 diabetes and one third 
of the women had Type 1 diabetes [12]. The preva-
lence of CHD was 83 per 1,000 offspring when HbA1c 
concentration was ≥ 69 mmol/mol (8.5%) and 39 per 
1,000 offspring when HbA1c concentration was < 69 
mmol/mol (8.5%) [12]. 
In the Danish study [14], the relative risk of CHD 
between offspring of women with Type 2 or Type 1 dia-
betes compared with the background population was 
approximately four, irrespective of the used treatment 
modality (diet alone, oral antidiabetic agents or  
in sulin). 
DISCUSSION 
This review identified five papers including an esti-
mated total of 23,845 offspring of women with Type 2 
diabetes and found a mean prevalence of CHD in the 
offspring of 44 per 1,000 offspring. The risk of CHD 
among the offspring of women with Type 2 diabetes 
was at the level of the offspring of women with Type 1 
diabetes and almost four times higher than the risk in 
the background population. 
The prevalence of CHD varied from 25.8 to 64.7 per 
1,000 offspring in the five included studies. The Danish 
[14] and the Canadian [9] studies used ICD-10 codes 
to identify CHD and reported similar results. The 
Taiwanese study [15] used the less specific ICD-9 co-
des, which might explain their comparatively higher 
prevalence of CHD [9, 14]. As expected, the highest 
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TABLE 1
The prevalence and relative risk of congenital heart defect in 22,746 women with Type 2 diabetes compared with the background population. 
Country Type of study Offspring, n
Method for  
diagnosis of defect
Inclusion of terminated 
pregnancies
Prevalence/1,000 
offspring
Risk in relation to  
background population Reference
USA Retrospective      371 Ante- and postnatal 
echocardiography
Yes 65 – [12]
Canada Population-based cohort   9,371a ICD-10 codes No 41 5.49 [9]
Taiwan Nationwide  
Population-based cohort
11,019b ICD-9 codes No 58 3.49 [15]
Denmark Nationwide  
Population-based cohort
  1,356 ICD-10 codes No 31 3.80 [14]
Norway Nationwide 
Population-based cohort
  1,728a ICD-10 codes Yes 26c 2.53 [13]
Total 23,845 44d 3.83
ICD-X = International Classification of Diseases, Xth revision.
a) Average prevalence of women with diabetes/offspring × the total number of offspring.
b) Total number of offspring with congenital heart defects in the group of women with diabetes/the prevalence of congenital heart defect in offspring of women with diabetes.
c) Relative risk in offspring of women with Type 2 diabetes × the prevalence in the background population: 10.2/1,000.
d) Mean value.
TABLE 2
Relative risk of congenital heart defect in women with Type 2 (T2D)- or Type 1 diabetes (T1D).
T2D T1D
Country offspring, n
risk in relation to  
background population (A) offspring, n risk in relation to background population (B) A/B Reference
Canada   9,371 5.49   7,800 6.32 0.87 [9]
Taiwan 11,019 3.49   3,975 6.61 0.53 [15]
Denmark   1,356 3.80   2,845 3.75 1.01 [14]
Norway   1,728 2.53   4,092 2.95 0.86 [13]
Total 23,474 3.83a 18,721 4.91a 0.82a
a) Mean value.
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prevalence was reported in the American study [12], 
where the CHD diagnosis was based on a neonatal 
echocardiography from live births and included aut-
opsies from miscarriages and terminated pregnancies. 
Both the Canadian and the Danish study found that 
the relative risk of CHD in offspring of women with 
Type 2 diabetes was increased compared with the back-
ground population [9, 14]. This is in line with the as-
sumption that the risk of CHD is increased when the  
foetus is exposed to elevated maternal glucose levels 
during organogenesis, as described in previous studies 
and reviews [16, 17]. Only one study [14] included 
data on the use of oral antidiabetic agents or insulin in 
relation to CHD and found no effect of treatment mo-
dality on the risk of malformations. Further studies are 
needed to elucidate the contribution of poor glycaemic 
control and treatment modality to the risk of CHD in 
offspring of women with Type 2 diabetes. 
In the Danish [14] and Norwegian [13] studies, the 
different types of CHD were evaluated, and all specific 
CHD phenotypes were associated with maternal pre-
gestational diabetes mellitus (relative risk ranges 2.74-
13.8 and 1.73-6.60, respectively).
A positive association between maternal HbA1c level 
in early pregnancy and the prevalence of CHD among 
the offspring of women with Type 2 and Type 1 diabe-
tes was found [12]. This is in line with findings in ani-
mal models [7, 8]. Two studies [13, 14] explored the 
relation between glycaemic control and CHD using sur-
rogate markers of elevated glycaemic levels as episodes 
with hospitalisation for acute diabetic complications 
such as ketoacidosis [14] or development of large-for-
gestational-age in infants [13]. Both studies [13, 14] 
found positive associations with a higher prevalence of 
CHD. Women with Type 2 diabetes often have better 
glycaemic control than women with Type 1 diabetes [4, 
12, 18, 19], but the risk of CHD is largely comparable 
in the offspring of women with Type 2 and Type 1 dia-
betes [9, 13, 14]. This could indicate that other risk fac-
tors influence the prevalence of CHD in women with 
Type 2 diabetes, i.e. a higher BMI and maternal age, et-
hnicity, lack of folic-acid supplementation and a poorer 
macro- and micronutrient intake, factors that are often 
associated with a lower socioeconomic status [4, 18-
20]. 
The strength of this study is the large sample size 
counting more than 23,000 offspring of women with 
Type 2 diabetes, 18,000 offspring of women with Type 
1 diabetes and data from offspring in the background 
population from various parts of the world. Further-
more, the literature search was conducted systematic-
ally in the PubMed, Embase and Cochrane databases 
and included both MESH terms (PubMed and Coch-
rane), subject headings (Embase) and text words. To 
clarify what could have caused the variation in the 
prevalence and the relative risks, it was described in 
detail how the studies differed, i.e. terminated preg-
nancies, chromosomal defects and diagnostic methods. 
It is a limitation that only studies published in the 
past ten years were included. Extending the search  
period would likely have revealed more studies, al-
though the further back the search dates, the fewer 
studies differentiate between Type 2 diabetes and Type 
1 diabetes. Based on a pragmatic judgement when 
planning this review, only studies with a minimum of 
200 offspring of women with Type 2 diabetes were in-
cluded. We did this to limit bias on the prevalence of 
CHD. This possibly excluded some studies, but only one 
study [12] included 371 women, and the remaining 
four studies each included more than one thousand off-
spring of women with Type 2 diabetes, which makes 
the assessment of the prevalence of CHD more precise. 
The included studies were heterogeneous with respect 
to method of diagnosis of CHD and whether terminated 
pregnancies were included or not. These factors could 
affect the prevalence estimates. Due to heterogeneity of 
the studies, it was not possible to perform a formal 
meta-analysis and sub-analysis.
CONCLUSIONS
The risk of CHD among offspring of women with Type 
2 diabetes was comparable to the risk in offspring of 
women with Type 1 diabetes and it was almost four 
times higher than the risk in the background popula-
tion. This calls for an enhanced focus on pregnancy 
planning in women with Type 2 diabetes and warrants 
more research into the pathophysiology and predicting 
factors of CHD.  
CORRESPONDENCE: Elisabeth R. Mathiesen. E­mail: elisabeth.reinhardt.
mathiesen@regionh.dk
ACCEPTED: 14 March 2019
CONFLICTS OF INTEREST: Disclosure forms provided by the authors are 
available with the full text of this article at Ugeskriftet.dk/dmj
LITERATURE
1. Jovanovic L, Liang Y, Weng W et al. Trends in the incidence of diabe­
tes, its clinical sequelae, and associated costs in pregnancy. Diab  
Metab Res Rev 2015;31:707­16.
2. Colstrup M, Mathiesen ER, Damm P et al. Pregnancy in women with 
type 1 diabetes: have the goals of St. Vincent declaration been met 
concerning foetal and neonatal complications? J Maternal­fetal  
Neonat Med 2013;26:1682­6.
3. Aberg A, Westbom L, Kallen B. Congenital malformations among in­
fants whose mothers had gestational diabetes or preexisting diabe­
tes. Early Hum Dev 2001;61:85­95.
4. Balsells M, Garcia­Patterson A, Gich I et al. Maternal and fetal outcome 
in women with type 2 versus type 1 diabetes mellitus: a systematic 
review and metaanalysis. J Clin Endocrin Metab 2009;94:4284­91.
5. Lapolla A, Dalfra MG, Fedele D. Pregnancy complicated by diabetes: 
what is the best level of HbA1c for conception? Acta Diabet 
2010;47:187­92.
6. Clapes S, Fernandez T, Suarez G. Oxidative stress and birth defects in 
infants of women with pregestational diabetes. MEDICC Rev 
2013;15:37­40.
7. Morgan SC, Relaix F, Sandell LL et al. Oxidative stress during diabetic 
pregnancy disrupts cardiac neural crest migration and causes out­
flow tract defects. Birth defects research Part A. Clin Molec Teratol 
2008;82:453­63.
8. Roest PA, van Iperen L, Vis S et al. Exposure of neural crest cells to  
elevated glucose leads to congenital heart defects, an effect that can 
5DANISH MEDICAL JOURNAL
Dan Med J 66/6  May 2019 
be prevented by N­acetylcysteine. Birth defects research Part A. Clin 
Molec Teratol 2007;79:231­5.
9. Liu S, Rouleau J, Leon JA et al. Impact of pre­pregnancy diabetes melli­
tus on congenital anomalies, Canada, 2002­2012. Health Promo Chron 
Dis Prev Canada 2015;35:79­84.
10. Liu S, Joseph KS, Lisonkova S et al. Association between maternal 
chronic conditions and congenital heart defects: a population­based 
cohort study. Circulation 2013;128:583­9.
11. Peticca P, Keely EJ, Walker MC et al. Pregnancy outcomes in diabetes 
subtypes: how do they compare? A province­based study of Ontario, 
2005­2006. J Obstet Gynaecol Canada 2009;31:487­96.
12. Starikov R, Bohrer J, Goh W et al. Hemoglobin A1c in pregestational di­
abetic gravidas and the risk of congenital heart disease in the fetus. 
Ped Cardiol 2013;34:1716­22.
13. Leirgul E, Brodwall K, Greve G et al. Maternal diabetes, birth weight, 
and neonatal risk of congenital heart defects in Norway, 1994­2009. 
Obstet Gynecol 2016;128:1116­25.
14. Oyen N, Diaz LJ, Leirgul E et al. Prepregnancy diabetes and offspring 
risk of congenital heart disease: a nationwide cohort study. Circula­
tion 2016;133:2243­53.
15. Chou HH, Chiou MJ, Liang FW et al. Association of maternal chronic 
disease with risk of congenital heart disease in offspring. CMAJ 
2016;188:E438­e46.
16. Priest JR, Yang W, Reaven G et al. Maternal midpregnancy glucose  
levels and risk of congenital heart disease in offspring. JAMA Ped 
2015;169:1112­6.
17. Simeone RM, Devine OJ, Marcinkevage JA et al. Diabetes and congen­
ital heart defects: a systematic review, meta­analysis, and modeling 
project. Am J Prev Med 2015;48:195­204.
18. Bell R, Glinianaia SV, Tennant PW et al. Peri­conception hyperglyc­
aemia and nephropathy are associated with risk of congenital anom­
aly in women with pre­existing diabetes: a population­based cohort 
study. Diabetologia 2012.
19. Murphy HR, Steel SA, Roland JM et al. Obstetric and perinatal out­
comes in pregnancies complicated by Type 1 and Type 2 diabetes: in­
fluences of glycaemic control, obesity and social disadvantage. Diab 
Med 2011;28:1060­7.
20. Block SR, Watkins SM, Salemi JL et al. Maternal pre­pregnancy body 
mass index and risk of selected birth defects: evidence of a dose­ 
response relationship. Paed Perinat Epidem 2013;27:521­31.
